TickerTalks
Browse all tickers →
TickerTalks›$YDES
YDYDES

YD Bio Limited Ordinary Shares

$YDES·$574M·Biotechnology·Healthcare
$5.79-1.5%YTD-73.5%1Y-66.1%
Price updated 9h ago·X counts updated 4d ago
YDYDES
$YDESYD Bio Limited Ordinary Shares
$5.79-1.53%61 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $YDES on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

61X posts · last 7 days
Sep 21Oct 4
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $YDES's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 79% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $YDES — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

YD Bio is a $400M micro-cap down 74% YTD — pre-revenue, no earnings date, thin signal.

YD Bio Limited is a clinical-stage biotech micro-cap. The business is pre-revenue and the data file in the bundle is limited.

  • The business is pre-revenue: PS 0, operating margin 0, PE -1.4 — standard clinical-stage biotech P&L where the thesis is pipeline and regulatory cadence.
  • 52-week range position is 30% at $7.81 with volume at 52% of average — mid-lower range on quiet volume, with 3 insider events in the bundle but no scheduled earnings.
  • At a $406M market cap the equity has lost 74% YTD and 56% TTM — meaningful drawdown with no visible stabilization trigger in the public data.

Absent a scheduled earnings date, this trades on announcements. Any pipeline data update or partnership disclosure is the first anchor; a dilutive raise is the clear negative risk.

What to watch: Next scheduled earnings release, pipeline-data updates, operating cash runway, and any partnership announcement. A dilutive raise is the clear invalidator.

thin bundle

Read the AI verdict on $YDES

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Taiwan clinical-stage biotech developing liquid biopsy cancer diagnostics and exosome-based therapeutics for diseases with unmet medical needs.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $YDES.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $YDES

Neutral — Taiwan clinical-stage biotech developing liquid biopsy cancer diagnostics and exosome-based therapeutics for diseases with unmet medical needs.

Top industry ETF

$IBBiShares Biotechnology ETF
+18.2%YTD
+31.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-6.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-0.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
52.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY25$0———$-0.65$-298K
Q1 FY25$0———$-0.98$-490K
Q4 FY24$0———$0.10$-366K
Q3 FY24$0———$0.54$-22K

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.20%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+39.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-3.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuySep 14Shen Ethan PhdCEO12.7K sh$49KBuySep 9Shen Ethan PhdCEO3.1K sh$12KBuySep 4Shen Ethan PhdCEO18.4K sh$67K
+ 8 other (4 exempts · 4 awards) in window

See when $YDES insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3/ANew insider — initial holdingsApr 203/A
+ 6 other (3 6-Ks · 1 EFFECT · 1 POS AM · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessmentglobenewswire.com·3d agoYD Bio (NASDAQ:YDES) Shares Down 4.4% – Here’s Whydefenseworld.net·7d agoYD Bio Limited (NASDAQ:YDES) Sees Large Increase in Short Interestdefenseworld.net·11d agoYD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026globenewswire.com·39d agoYD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Instituteglobenewswire.com·45d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$KOD$MRNA$IOVA$ARCT$IBRX$VKTX$NWBO$QURE
Voices on X · last 7 days

No standout posts about $YDES on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport